Advanced Search

 

Study ID Status Title Patient Level Data
NAIB2007 Completed Double-Blind, Randomised, Placebo-Controlled, Multicentre Study to Investigate the Efficacy and Safety of Inhaled and Inhaled plus Intranasal GG167 in the Treatment of Influenza A and B Viral Infections Study Listed on ClinicalStudyDataRequest.com
NAIB2008 Completed A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Investigate the Efficacy and Safety of GG167 Administered Twice or Four Times a Day for the Treatment of Influenza A and B Viral Infections Study Listed on ClinicalStudyDataRequest.com
NAIB2009 Completed A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Investigate the Efficacy and Safety of GG167 in the Prevention and/or Progression of Influenza A and B Viral Infections Study Listed on ClinicalStudyDataRequest.com
NAIB3001 Completed A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir administered twice daily in the treatment of influenza A and B viral infections in adults. Study Listed on ClinicalStudyDataRequest.com
NAIB3002 Completed A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults. Study Listed on ClinicalStudyDataRequest.com
NKB104846 Terminated A randomized, double-blind, placebo-controlled, crossover study (Part 1) and parallel group design study (Part 2) to evaluate the effects of GW679769 on Current Perception Threshold (CPT) following a single dose and the effect on CPT and symptoms of overactive bladder (OAB) following 28 days of repeat dosing in Patients with Neurogenic Bladder due to Upper Motor Neuron (UMN) Disease
NKB105022 Completed NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder symptoms
NKD10020 Completed A double-blind, double dummy, randomised, parallel group positron emission tomography study to investigate the effects of chronic administration of an oral dose of GW597599, paroxetine 20mg or placebo on regional cerebral blood flow, using the tracer [15O]-water, in subjects affected by social phobia Study Listed on ClinicalStudyDataRequest.com
NKD20006 Completed An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed-Dose Study Comparing the Efficacy and Safety of GW597599B or Paroxetine to Placebo in Moderately to Severely Depressed Patients with Major Depressive Disorder Study Listed on ClinicalStudyDataRequest.com
NKE10001 Completed An open-label, repeat-dose, randomized, three-period crossover, parallel-group study to investigate the potential pharmacokinetic interactions between two doses of a new chemical entity (NCE) and ondansetron (OND) and dexamethasone (DEX) when co-administered in healthy adult subjects.
NKE20001 Completed A Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Parallel Group Study of the Efficacy and Safety of a New Chemical Entity When Administered as Oral Tablets in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induc ...
NKF100092 Completed A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects with Major Depressive Disorder.
NKF100096 Completed A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Major depressive Disorder (MDD) Study Listed on ClinicalStudyDataRequest.com
NKF100110 Completed A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Social Anxiety Disorder Study Listed on ClinicalStudyDataRequest.com
NKG10006 Completed A Randomized, Double-Blind, Placebo-Controlled, Three Armed fMRI study Comparing Emotion-Induced Brain Activation Patterns Before and After 8 Weeks of Treatment With Placebo, Active Comparator (PAXIL, 20 mg), and a GSK New Chemical Entity (NCE) Study Listed on ClinicalStudyDataRequest.com
NKI110334 Completed A multi-centre, randomized, double-blind, placebo-controlled, cross-over study to evaluate the effects of GW597599 and GR205171 on sleep continuity, PSG sleep recordings, subjective sleep assessment and daytime cognitive function in subjects with primary insomnia Study Listed on ClinicalStudyDataRequest.com
NKP102280 Completed A double-blind, triple dummy, placebo-controlled, randomised, parallel group positron emission tomography study to investigate the effects of a 8 week administration of GW597599 and paroxetine either alone or in combination on regional cerebral blood flow during a public speaking test in subjects affected by social phobia. Study Listed on ClinicalStudyDataRequest.com
NKP103401 Completed A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/paroxetine combination or paroxetine monotherapy to placebo in Patients with Social Anxiety Disorder (SAD) Study Listed on ClinicalStudyDataRequest.com
NKP106254 Completed Randomised, double-blind, placebo controlled, cross-over study comparing the effects of both single dose and repeated dosing treatment for 14 days of vestipitant or vestipitant / paroxetine combination in an enriched population of subjects with tinnitus & hearing loss Study Listed on ClinicalStudyDataRequest.com
NKT102245 Completed See Detailed Description
NKT102260 Completed See Detailed Description
NKT102552 Completed A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis Study Listed on ClinicalStudyDataRequest.com
NKT102553 Completed A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50mg Oral Dosing with the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis Study Listed on ClinicalStudyDataRequest.com
NKT102783 Completed An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects with Renal Impairment Study Listed on ClinicalStudyDataRequest.com
NKT102785 Completed An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in subjects with Hepatic Impairment Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.